SG Americas Securities
TPST icon

SG Americas Securities’s Tempest Therapeutics TPST Stock Holding History

SG Americas Securities’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-10
Closed -$55K – 3518
2017
Q1 		$55K Buy
+10
New +$46.6K ﹤0.01% 3102
2016
Q4 		– Sell
-4
Closed -$74K – 3455
2016
Q3 		$74K Buy
+4
New +$72.4K ﹤0.01% 3133
2015
Q3 		– Sell
-1
Closed -$110K – 2680
2015
Q2 		$110K Buy
+1
New +$91.6K ﹤0.01% 2312

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SG Americas Securities's TPST Position: Q2 2017 in Review

SG Americas Securities sold out of Tempest Therapeutics (TPST) in Q2 2017, closing a stake of 10 shares — an estimated $55K sold.

SG Americas Securities first reported a position in TPST in Q2 2015 and held it in 3 quarters. The position peaked at $110K in Q2 2015. 54 funds tracked by Wall St. Rank hold TPST as of Q2 2017.

  • SG Americas Securities reported no remaining Tempest Therapeutics position as of Q2 2017 after selling out during the quarter.
  • SG Americas Securities sold 10 Tempest Therapeutics shares in Q2 2017, an estimated $55K.
  • SG Americas Securities first reported a position in Tempest Therapeutics in Q2 2015 and held it in 3 quarters.
  • SG Americas Securities's Tempest Therapeutics position peaked at $110K in Q2 2015.
  • 54 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2017.

Based on SG Americas Securities's 13F filing for Q2 2017, filed 3 Aug 2017.